Vancomycin disposition: the importance of age
- PMID: 6499360
- DOI: 10.1038/clpt.1984.260
Vancomycin disposition: the importance of age
Abstract
We examined the influence of age on vancomycin kinetics in 12 normal healthy men (six young and six elderly) after an intravenous infusion of 6 mg/kg. Serial blood and urine samples were collected for up to 2 days after dosing and were assayed for unchanged drug by a specific radioimmunoassay. Serum concentrations of vancomycin after infusion declined in a multiphasic manner. Both serum and urinary excretion data were simultaneously fit by a three-compartment model with SAAM-27 computer programs. Estimates of mean t1/2 obtained from the terminal phase of the drug disposition profile showed the t1/2 to be longer in the elderly than in the young subjects (12.1 and 7.2 hr). Although there was no change in the initial distribution volume of the central compartment, total systemic and renal clearances were reduced in the elderly and did not correlate with renal function. The increase in the vancomycin volume of distribution at steady state was ascribed to enhanced tissue binding of drug in the elderly, since the mean fraction of vancomycin bound in systemic pool of the young and elderly did not differ (0.53 and 0.56). In-depth analysis of excretion data tends to support suggestions of vancomycin excretion solely by glomerular filtration. Our data strongly suggest the need for adjustment or modification of recommended vancomycin dosing schedules in the elderly.
Similar articles
-
Clinical pharmacokinetics of vancomycin.Clin Pharmacokinet. 1986 Jul-Aug;11(4):257-82. doi: 10.2165/00003088-198611040-00001. Clin Pharmacokinet. 1986. PMID: 3530582 Review.
-
Vancomycin elimination in patients with burn injury.Clin Pharmacol Ther. 1986 Jun;39(6):631-4. doi: 10.1038/clpt.1986.111. Clin Pharmacol Ther. 1986. PMID: 3709027
-
Single-dose kinetics of intravenous vancomycin.J Clin Pharmacol. 1980 Apr;20(4):197-201. doi: 10.1002/j.1552-4604.1980.tb01696.x. J Clin Pharmacol. 1980. PMID: 7381031
-
Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function.Rev Infect Dis. 1981 Nov-Dec;3 suppl:S230-5. Rev Infect Dis. 1981. PMID: 7342286
-
Vancomycin: an update.Pharmacotherapy. 1986 Jul-Aug;6(4):153-69. doi: 10.1002/j.1875-9114.1986.tb03471.x. Pharmacotherapy. 1986. PMID: 3534799 Review.
Cited by
-
Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males.Eur J Clin Pharmacol. 1988;34(2):179-86. doi: 10.1007/BF00614556. Eur J Clin Pharmacol. 1988. PMID: 3289950
-
Clinical pharmacokinetics of vancomycin.Clin Pharmacokinet. 1986 Jul-Aug;11(4):257-82. doi: 10.2165/00003088-198611040-00001. Clin Pharmacokinet. 1986. PMID: 3530582 Review.
-
Age-related changes in protein binding of drugs: implications for therapy.Clin Pharmacokinet. 2000 Mar;38(3):271-90. doi: 10.2165/00003088-200038030-00005. Clin Pharmacokinet. 2000. PMID: 10749520 Review.
-
Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.Antimicrob Agents Chemother. 2011 Sep;55(9):4277-82. doi: 10.1128/AAC.01674-10. Epub 2011 Jun 13. Antimicrob Agents Chemother. 2011. PMID: 21670191 Free PMC article.
-
Vancomycin: a review of population pharmacokinetic analyses.Clin Pharmacokinet. 2012 Jan 1;51(1):1-13. doi: 10.2165/11596390-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22149255 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical